Generic Tazorac Availability

Tazorac is a brand name of tazarotene topical, approved by the FDA in the following formulation(s):

TAZORAC (tazarotene - cream;topical)

  • Manufacturer: ALLERGAN
    Approval date: September 29, 2000
    Strength(s): 0.05% [RLD], 0.1% [RLD]

TAZORAC (tazarotene - gel;topical)

  • Manufacturer: ALLERGAN
    Approval date: June 13, 1997
    Strength(s): 0.05% [RLD], 0.1% [RLD]

Has a generic version of Tazorac been approved?

No. There is currently no therapeutically equivalent version of Tazorac available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tazorac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Stable gel formulation for topical treatment of skin conditions
    Patent 5,914,334
    Issued: June 22, 1999
    Inventor(s): Charu; Prakash M.
    Assignee(s): Allergan, Inc.
    The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.
    Patent expiration dates:
    • June 7, 2014
      ✓ 
      Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
  • Stable gel formulation for topical treatment of skin conditions
    Patent 6,258,830
    Issued: July 10, 2001
    Inventor(s): Charu; Prakash M.
    Assignee(s): Allergan Sales, Inc.
    The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.
    Patent expiration dates:
    • June 7, 2014
      ✓ 
      Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)